Genius 3D Mammography

19,605,342 women in America will get breast cancer in their lifetime1

Insurance Companies, please cover
GeniusTM 3D MAMMOGRAPHYTM exams in full.

GeniusTM 3D MAMMOGRAPHYTM exams are more accurate screening procedures available in the fight against breast cancer. Many insurance companies do not provide full coverage for digital breast tomosynthesis, which affects patients' right to choose the best possible option for early breast cancer detection.

  • $550+ million
    could be saved annually in US breast cancer health care spending2 with the use of 3D MAMMOGRAPHYTM exams.

  • 10+ million
    women

    have been screened with a GeniusTM 3D MAMMOGRAPHYTM exam since 2011.

  • 66% of
    women

    would consider switching insurance companies for coverage of 3D MAMMOGRAPHYTM exams.3

  • 3D
    MAMMOGRAPHYTM exams substantially reduce the need for follow up diagonistic services and improves detection of invasive cancers, allowing for earlier, less costly treatment.2

  • 1 in every 8
    women

    will develop breast cancer within her lifetime.4

  • Almost 100%
    is the 5-year survival rate when breast cancer is found early.5

Advantages of Genius Exams

  • More accurate than conventional 2D mammography, offering a 41% increase in the detection of invasive breast cancers.6, 7-11
  • Up to a 50% reduction in callbacks due to "false positives," helping to eliminate unnecessary, and potentially costly, additional imaging exams.6,9
  • Covered and paid for by Medicare, available in all 50 states, and endorsed by major medical organizations, including the:
    • American Society of Breast Disease (ASBD)
    • American Congress of Obstetricians and Gynecologists (ACOG)
    • American College of Radiology (ACR)
Learn More

Insurance Companies

Your customers are depending on you. Add full coverage for GeniusTM 3D MAMMOGRAPHYTM exams to your plans today!



Contact our Health Economics Team:
tomocoverage@hologic.com

Women

You deserve better.

Tell your insurer that you want full coverage for a GeniusTM 3D MAMMOGRAPHYTM exam.



Demand Full Coverage Today

Cost Benefit Analysis

Value analysis of digital breast tomosynthesis (DBT) for breast cancer screening in a commercially-insured US population concludes that the adoption of GeniusTM 3D MAMMOGRAPHYTM exams can save the US Healthcare System millions of dollars. The results of the model analyses comparing full field digital mammography (FFDM) with FFDM + DBT are shown in the table below.

DBT Value Analysis Results2

Base Case Analysis Range Analysis
Patients Utilizing
Follow-Up Services
Follow-up Services
Rate for FFDM=15.35% and FFDM+DBT=10.00%
Follow-up Services
Rate for FFDM=15.35% and FFDM+DBT=8.00%
Follow-up Services
Rate for FFDM=15.35% and FFDM+DBT=9.00%
Follow-up Services
Rate for FFDM=15.35% and FFDM+DBT=11.00%
Follow-up Services
Rate for FFDM=15.35% and FFDM+DBT=12.00%
Current scenario with FFDM 12,978 12,978 12,978 12,978 12,978
Revised scenario with FFDM + DBT 8,455 6,764 7,609 9,300 10,146
Difference (number of follow-ups averted due to use of DBT) 4,523 6,214 5,369 3,678 2,832
Total Costs
Current scenario with FFDM $54,629,680 $54,629,680 $54,629,680 $54,629,680 $54,629,680
Revised scenario with FFDM + DBT $52,217,369 $50,179,239 $51,198,303 $53,236,432 $54,255,497
Difference (total costs savings due to use of DBT) $2,412,312 $4,450,441 $3,431,376 $1,393,247 $374,183
Additional expense of DBT for screening -$4,277,466 -$4,277,466 -$4,277,466 -$4,277,466 -$4,277,466
Attributable to reduction in follow-ups $5,451,994 $7,490,123 $6,471,059 $4,432,930 $3,413,866
Attributable to earlier detection of breast cancer $1,187,783 $1,187,783 $1,187,783 $1,187,783 $1,187,783
Per Patient Costs
Current scenario with FFDM $646.13 $646.13 $646.13 $646.13 $646.13
Revised scenario with FFDM + DBT $617.60 $539.49 $605.54 $629.65 $641.70
Difference (total costs savings due to use of DBT) $28.53 $52.64 $40.48 $16.48 $4.43
Additional expense of DBT for screening -$50.00 -$50.00 -$50.00 -$50.00 -$50.00
Attributable to reduction in follow-ups $64.48 $88.59 $76.54 $52.43 $40.38
Attributable to earlier detection of breast cancer $14.05 $14.05 $14.05 $14.05 $14.05
Per Member, Per Month Costs
Current scenario with FFDM $4.55 $4.55 $4.55 $4.55 $4.55
Revised scenario with FFDM + DBT $4.35 $4.18 $4.27 $4.44 $4.52
Difference (savings PMPM due to DBT) $0.20 $0.37 $0.29 $0.12 $0.03
  1. http://quickfacts.census.gov/qfd/states/00000.html
  2. Bonafede, Machaon M., Vivek B. Kalra, Jeffrey D. Miller, and Laurie L. Fajardo. Value Analysis of Digital Breast Tomosynthesis for Breast Cancer Screening in a Commercially-insured US Population. Rep. N.p.: ClinicoEconomics and Outcomes Research, 2015. Print.
  3. Patel H. Women want breast cancer screening with better detection and fewer follow-up tests [press release]. Society for Women’s Health Research. http://swhr.org/resource/ women-want-breast-cancer-screening-with-better-detection-and-fewer-follow-up-tests/. Published October 31, 2014. Accessed April 8, 2015.
  4. US breast cancer statistics. Breastcancer.org. http://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed on: March 27, 2015.
  5. National Breast Cancer Foundation, Inc. Stages 0 & 1: what does is mean to have stage 1 breast cancer? National Breast Cancer Foundation, Inc. http://www.nationalbreastcancer.org/breast-cancer-stage-0-and-1. Accessed on: March 31, 2015.
  6. Friedewald S, Rafferty E, Rose S, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499-2507.
  7. Skaane P, Bandos A, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013;267(1):47-56.
  8. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14(7):583-589.
  9. Rose S, Tidwell A, Bujnock L, et al. Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR AM J Roentgenol. 2013;200(6):1401-1408.
  10. McCarthy A, Kontos D, Synnestvedt M, et al. Screening outcomes following implantation of digital breast tomosynthesis in a general-population screen program. J Natl Cancer Inst. 2014;106(11).
  11. Greenberg J, Javitt M, Katzen J, et al. Clinical performance metrics of 3D digital breast tomosynthesis compared with 2D digital mammography for breast cancer screening in community practice. AJR AM J Roentgenol. 2014;203:687-693.